



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/825,472

04/15/2004

Robert H. Zimmer

98204.00024

8345

72535

7590

10/28/2008

MCCARTER & ENGLISH, LLP STAMFORD OFFICE
FINANCIAL CENTRE, SUITE 304A
695 EAST MAIN STREET
STAMFORD, CT 06901-2138

EXAMINER

TELLER, ROY R

ART UNIT

PAPER NUMBER

1654

MAIL DATE

DELIVERY MODE

10/28/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/825,472	Applicant(s) ZIMMER, ROBERT H.	
	Examiner ROY TELLER	Art Unit 1654	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 22 July 2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-17, 25 and 26 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-17, 25-26 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1654

DETAILED ACTION

This office action is in response to the amendment, received 7/22/08, in which applicant amended claims 1, 2, and 25; and added new claim 26.

Claims 1-17 and 25-26 are under examination.

Response to Amendments/ Arguments

Applicant's arguments and amendments filed 7/22/08 are acknowledged and have been fully considered. Any rejection and or objection not specifically addressed is herein withdrawn.

Claim Rejections - 35 USC § 112

Claims 1-17 and 25 are/stand rejected under 35 USC 112, first paragraph for the reasons of record which are restated below.

Claims 1-17 and 25 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

This is a "written description" rejection, rather than an enablement rejection under 35 U.S.C. 112, first paragraph. Applicant is directed to the Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112, ¶ 1 "Written Description" Requirement, Federal Register, Vol. 66, No. 4, pages 1099-1111, Friday January 5, 2001.

Art Unit: 1654

The factors considered in the Written Description requirement are (1) level of skill and knowledge in the art, (2) partial structure, (3) physical and/or chemical properties, (4) functional characteristics alone or coupled with a known or disclosed correlation between structure and function, and the (5) method of making the claimed invention.

In the instant case, the claims are drawn to a pharmaceutical agent having the formula:
Carrier-Linker-Peptide.

(1) Level of skill and knowledge in the art:

The level of skill to practice the art of the instantly claimed invention is high with regard to conception, synthesis, and experimental protocols and data analysis of experimental results.

(2) Partial structure: (3) Physical and/or chemical properties: and (4) Functional characteristics: Wherein the peptide is a peptide having the formula aa_n , wherein peptide is Tyr-Gly-Gly-Phe-Met, carrier is a cinnamoyl and combinations thereof and wherein the linker is -C6 or C8 acididic moiety and derivatives thereof.

Vas-Cath Inc. V. Mahurka, 19 USPQ2d 1111, states that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention, for purposes of the “written description” inquiry, is *whatever is now claimed*” (see page 1117).

A review of the language of the claim indicates that these claims are drawn to a genus, i.e., the genus of a pharmaceutical agent having the formula : carrier-linker-peptide, wherein the peptide is a peptide having the formula aa_n , wherein peptide is Tyr-Gly-Gly-Phe-Met, carrier is a cinnamoyl and combinations thereof and wherein the linker is -C6 or C8 acididic moiety and combinations, pseudopeptides, and peptide mimics thereof.

Art Unit: 1654

A description of a genus may be achieved by means of a recitation of a representative number of species falling within the scope of the genus or of a recitation of structural features common to the members of the genus, which features constitute a substantial portion of the genus. *Regents of the University of California v. Eli Lilly & Co.*, 119 F3d 1559, 1569, 43 USPQ2d 1398, 1406 (Fed. Cir. 1997). In *Regents of the University of California v. Eli Lilly* (43 USPQ2d 1398-1412), the court held that a generic statement which defines a genus of nucleic acids by only their functional activity does not provide an adequate written description of the genus. The court indicated that, while applicants are not required to disclose every species encompassed by a genus, the description of the genus is achieved by the recitation of a representative number of species falling within the scope of the claimed genus. At section B(1), the court states “An adequate written description of a DNA ... requires a precise definition, such as by structure, formula, chemical name, or physical properties, not a mere wish or plan for obtaining the claimed chemical invention”.

There is a single species of the claimed genus disclosed that is within the scope of the claimed genus, *i.e.* wherein peptide is Tyr-Gly-Gly-Phe-Met, carrier is a cinnamoyl and wherein the linker is –C6 or C8 acidide moiety. The disclosure of a single disclosed species may provide an adequate written description of a genus when the species disclosed is representative of the genus. However, the present claim encompasses numerous species of combinations and pharmaceutical agents with an immune sequence characteristic of an infectious, viral or cancerous disease that are not further described and there is substantial variability among the species. No single claim is drawn to a single species which is fully defined.

Art Unit: 1654

One of skill in the art would not recognize from the disclosure that the applicant was in possession of the genus of which comprises the genus of derivatives of the carrier and the linker. The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed” (see *Vas-Cath* at page 1116).

Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. 112 is severable from its enablement provision (see page 1115).

All other claims depend directly or indirectly from the rejected claim and are, therefore, also rejected under 35 USC 112, first paragraph for the reasons set forth above.

Applicant's arguments were carefully considered but were not found persuasive. Applicant contends that, generally, the more sophisticated that a person of skill in the art would be, the less disclosure is necessary to satisfy the written description requirement. Further, there is a strong presumption that an adequate written description of the claimed invention is present when the application is filed. Applicant contends that the examiner is improperly attempting to limit the scope of the claims based on the description of certain preferred embodiments.

However, the examiner contends that the present claim encompasses numerous species that are not further described and that there is substantial variability among the species. Absent further disclosure from applicant, a written description rejection is appropriate. Further, the examiner contends that the instant specification must provide an enabling disclosure of the claimed subject matter; mere naming or description of the claimed subject matter is insufficient, if it cannot be produced without undue experimentation. One species of the claimed genus was fully disclosed; wherein peptide is Tyr-Gly-Gly-Phe-Met, carrier is a cinnamoyl and wherein the linker is –C6 or C8 acidide moiety. The disclosure of a single disclosed species may

Art Unit: 1654

provide an adequate written description of a genus when the species disclosed is representative of the genus. However, the present claim encompasses numerous species of combinations and pharmaceutical agents with an immune sequence characteristic of an infectious, viral or cancerous disease that are not further described and there is substantial variability among the species. No single claim is drawn to a single species which is fully defined.

Therefore, the claimed invention is deemed to lack adequate written description for the reasons set forth above.

Claims 1-17 and 25 are/stand rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for peptide is Tyr-Gly-Gly-Phe-Met, carrier is a cinnamoyl and wherein the linker is –C6 or C8 acidide moiety, does not reasonably provide enablement for a pharmaceutical agent having the formula : carrier-linker-peptide, wherein the peptide is a peptide having the formula aa_n , where n is an integer-40, carrier is an aryl or alkyl group and combinations thereof and wherein the linker is –C6 or C13 acidide moiety and combinations, pseudopeptides, and peptide mimics thereof.

The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

In this regard, the application disclosure and claims have been compared per the factors indicated in the decision *In re Wands*, 8 USPQ2d 1400 (Fed. Cir., 1988) as to undue experimentation. The factors include:

- 1) the nature of the invention;
- 2) the breadth of the claims;

Art Unit: 1654

- 3) the predictability or unpredictability of the art
- 4) the amount of direction or guidance presented;
- 5) the presence or absence of working examples;
- 6) the quantity of experimentation necessary;
- 7) the state of the prior art; and,
- 8) the relative skill of those skilled in the art;

Each factor is addressed below on the basis of comparison of the disclosure, the claims and the state of the prior art in the assessment of undue experimentation.

The claimed invention is drawn to a pharmaceutical agent having the formula : carrier-linker-peptide, wherein the peptide is a peptide having the formula aa_n , where n is an integer-40, carrier is an aryl or alkyl group and combinations thereof and wherein the linker is -C6 or C13 acidide moiety and combinations, pseudopeptides, and peptide mimics thereof.

The breadth of the claims is excessive with regard to a pharmaceutical agent having the formula : carrier-linker-peptide, wherein the peptide is a peptide having the formula aa_n , where n is an integer-40, carrier is an aryl or alkyl group and combinations thereof and wherein the linker is -C6 or C13 acidide moiety and combinations, pseudopeptides, and peptide mimics thereof.

Applicant has only provided guidance for a peptide is Tyr-Gly-Gly-Phe-Met, carrier is a cinnamoyl and wherein the linker is -C6 or C8 acidide moiety. Applicant have provided no guidance of any other therapeutic peptide having less than or equal to 40 amino acid residues, or carrier moieties that can be either of a particular chemical species or derivatives thereof.

In consideration of these factors, it is apparent that there is undue experimentation because of a variability in prediction of outcome that is not addressed by the present application.

Absent factual data to the contrary, the amount and level of experimentation needed is undue to

Art Unit: 1654

practice the invention as claimed.

Accordingly, with respect to the elected invention, others skilled in the art would be unable to practice the invention as claimed without undue experimentation and with a reasonable expectation of success, other than using a peptide is Tyr-Gly-Gly-Phe-Met, carrier is a cinnamoyl and wherein the linker is -C6 or C8 acidide moiety.

Applicant's arguments were carefully considered but were not found persuasive.

Applicant contends that, generally, the more sophisticated that a person of skill in the art would be, the less disclosure is necessary to satisfy the enablement requirement. Applicant contends that the examiner is improperly attempting to limit the scope of the claims based on the description of certain preferred embodiments.

However, the examiner contends that the present claim encompasses numerous species that are not further described and that there is substantial variability among the species. Absent further disclosure from applicant, a scope of enablement rejection is appropriate. Further, the examiner contends that the instant specification must provide an enabling disclosure of the claimed subject matter; mere naming or description of the claimed subject matter is insufficient, if it cannot be produced without undue experimentation. One species of the claimed genus was fully disclosed; wherein peptide is Tyr-Gly-Gly-Phe-Met, carrier is a cinnamoyl and wherein the linker is -C6 or C8 acidide moiety. However, the present claim encompasses numerous species of combinations and pharmaceutical agents with an immune sequence characteristic of an infectious, viral or cancerous disease that are not further described and there is substantial variability among the species. No single claim is drawn to a single species which is fully defined.

New Rejection

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claim 26 is rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 3 7 and 9-14 of U.S. Patent No.6,908,900. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant invention is drawn to a pharmaceutical agent having the formula : carrier-linker-peptide, wherein the peptide is Tyr-Gly-Gly-Phe-Met, carrier is a cinnamoyl and wherein the linker is – C6 or C8 acidide moiety.

The ‘900 patent is drawn to a pharmaceutical agent comprising a carrier moiety and a peptide species, wherein the carrier moiety is chemically linked to the peptide, wherein the peptide comprises Tyr-Gly-Gly-Gly-Phe-Met and wherein the carrier is cinnamoyl. The linker

Art Unit: 1654

species is directly bound to the carrier. Alternatively, the linker species is bound to the carrier through a –C6 or-C8 acidic moiety. More preferably, the linker species is Gly-carba-Gly, a pseudo-peptide. See, i.e, for example, abstract, column 2, lines 29-65, column 6, lines 54-60, and claims 1, 3, 7, and 9-14.

Claim 26 is directed to an invention not patentably distinct from claims 1, 3, 7, and 9-14 of commonly assigned USPN 6,908,900. Specifically, although the conflicting claims are not identical, they are not patentably distinct from each other because the instant invention is drawn to a pharmaceutical agent having the formula : carrier-linker-peptide, wherein the peptide is a peptide Tyr-Gly-Gly-Phe-Met, carrier is a cinnamoyl and wherein the linker is –C6 or C8 acidide moiety.

The '900 patent is drawn to a pharmaceutical agent comprising a carrier moiety and a peptide species, wherein the carrier moiety is chemically linked to the peptide, wherein the peptide comprises Tyr-Gly-Gly-Gly-Phe-Met and wherein the carrier is cinnamoyl. The linker species is directly bound to the carrier. Alternatively, the linker species is bound to the carrier through a –C6 or-C8 acidic moiety. More preferably, the linker species is Gly-carba-Gly, a pseudo-peptide. See, i.e, for example, abstract, column 2, lines 29-65, column 6, lines 54-60, and claims 1, 3, 7, and 9-14. The U.S. Patent and Trademark Office normally will not institute an interference between applications or a patent and an application of common ownership (see MPEP Chapter 2300). Commonly assigned USPN 6,908,900, discussed above, would form the basis for a rejection of the noted claims under 35 U.S.C. 103(a) if the commonly assigned case qualifies as prior art under 35 U.S.C. 102(e), (f) or (g) and the conflicting inventions were not commonly owned at the time the invention in this application was made. In order for the

Art Unit: 1654

examiner to resolve this issue, the assignee can, under 35 U.S.C. 103(c) and 37 CFR 1.78(c), either show that the conflicting inventions were commonly owned at the time the invention in this application was made, or name the prior inventor of the conflicting subject matter.

A showing that the inventions were commonly owned at the time the invention in this application was made will preclude a rejection under 35 U.S.C. 103(a) based upon the commonly assigned case as a reference under 35 U.S.C. 102(f) or (g), or 35 U.S.C. 102(e) for applications pending on or after December 10, 2004.

Conclusion

All claims are rejected.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a).

Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Art Unit: 1654

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Roy Teller whose telephone number is 571-272-0971. The examiner can normally be reached on Monday-Friday from 5:30 am to 2:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang, can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

RT
1654
10/23/08

/Christopher R. Tate/
Primary Examiner, Art Unit 1655